Group Health Research Institute, Kaiser Permanente Research Affiliates Evidence-based Practice Center, Seattle, Washington.
Kaiser Permanente Center for Health Research, Kaiser Permanente Research Affiliates Evidence-Based Practice Center, Portland, Oregon.
JAMA. 2016 Aug 9;316(6):634-44. doi: 10.1001/jama.2016.6423.
IMPORTANCE: Multifactorial dyslipidemia, characterized by elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C), is associated with dyslipidemia and markers of atherosclerosis in young adulthood. Screening for dyslipidemia in childhood could delay or reduce cardiovascular events in adulthood. OBJECTIVE: To systematically review the evidence on benefits and harms of screening adolescents and children for multifactorial dyslipidemia for the US Preventive Services Task Force (USPSTF). DATA SOURCES: MEDLINE, Cochrane Central Register of Controlled Trials, and PubMed were searched for studies published between January 1, 2005, and June 2, 2015; studies included in a previous USPSTF evidence report and reference lists of relevant studies and ongoing trials were also searched. Surveillance was conducted through April 9, 2016. STUDY SELECTION: Fair- and good-quality studies in English with participants 0 to 20 years of age. DATA EXTRACTION AND SYNTHESIS: Two investigators independently reviewed abstracts and full-text articles and extracted data into evidence tables. Results were qualitatively summarized. MAIN OUTCOMES AND MEASURES: Outcomes included dyslipidemia (TC≥200 mg/dL or LDL-C≥130 mg/dL) and atherosclerosis in childhood; myocardial infarction and ischemic stroke in adulthood; diagnostic yield (number of confirmed cases per children screened); and harms of screening or treatment. Simulated diagnostic yield was calculated as initial screening yield × positive predictive value from a study with confirmatory testing. RESULTS: Screening of children for multifactorial dyslipidemia has not been evaluated in randomized clinical trials. Based on 1 observational study (n = 6500) and nationally representative prevalence estimates, the simulated diagnostic yield of screening for elevated TC varies between 4.8% and 12.3% (higher in obese children [12.3%] and at the ages when TC naturally peaks-7.2% at age 9-11 years and 7.2% at age 16-19 years). One good-quality randomized clinical trial (n = 663) found a modest effect of intensive dietary counseling for a low-fat, low-cholesterol diet on lipid levels at 1 year in children aged 8 to 10 years with mild to moderate dyslipidemia; mean between-group difference in TC change from baseline was -6.1 mg/dL (95% CI, -9.1 to -3.2 mg/dL; P < .001). Between-group differences dissipated by year 5. The intervention did not adversely affect nutritional status, growth, or development over the 18-year study period. One observational study (n = 9245) found that TC concentration at age 12 to 39 years was not associated with death before age 55 years. CONCLUSIONS AND RELEVANCE: The diagnostic yield of lipid screening varies by age and body mass index. No direct evidence was identified for benefits or harms of childhood screening or treatment on outcomes in adulthood. Intensive dietary interventions may be safe, with modest short-term benefit of uncertain clinical significance.
重要提示:以总胆固醇(TC)或低密度脂蛋白胆固醇(LDL-C)升高为特征的多种因素引起的血脂异常与青年成年人的血脂异常和动脉粥样硬化标志物有关。在儿童期筛查血脂异常可能会延迟或减少成年后的心血管事件。
目的:系统评价美国预防服务工作组(USPSTF)对青少年和儿童进行多种因素血脂异常筛查的益处和危害。
数据来源:2005 年 1 月 1 日至 2015 年 6 月 2 日,检索 MEDLINE、Cochrane 对照试验中心注册库和 PubMed 数据库,还检索了之前 USPSTF 证据报告中的研究和相关研究及正在进行的试验的参考文献列表。通过 2016 年 4 月 9 日进行监测。
研究选择:参与者年龄为 0 至 20 岁的英语研究,具有良好和良好的质量。
数据提取和综合:两名研究人员独立审查摘要和全文文章,并将数据提取到证据表中。结果进行了定性总结。
主要结果和措施:结果包括儿童期血脂异常(TC≥200mg/dL 或 LDL-C≥130mg/dL)和动脉粥样硬化;成年期心肌梗死和缺血性中风;筛查的诊断收益(每筛查儿童确诊病例数);以及筛查或治疗的危害。模拟诊断产量计算为初始筛查产量乘以具有确认性测试的研究的阳性预测值。
结果:尚未在随机临床试验中评估儿童多种因素血脂异常的筛查。基于 1 项观察性研究(n=6500)和全国代表性流行率估计,筛查 TC 升高的模拟诊断产量在 4.8%至 12.3%之间变化(在肥胖儿童中更高[12.3%],在 TC 自然升高的年龄-9 至 11 岁时为 7.2%,在 16 至 19 岁时为 7.2%)。一项高质量的随机临床试验(n=663)发现,在 8 至 10 岁轻度至中度血脂异常的儿童中,进行强化饮食咨询以进行低脂、低胆固醇饮食,在 1 年内对血脂水平有适度影响;TC 基线变化的组间平均差异为-6.1mg/dL(95%CI,-9.1 至-3.2mg/dL;P<0.001)。组间差异在第 5 年就消失了。该干预措施在 18 年的研究期间并未对营养状况、生长或发育产生不利影响。一项观察性研究(n=9245)发现,12 至 39 岁时的 TC 浓度与 55 岁前的死亡无关。
结论和相关性:血脂筛查的诊断产量因年龄和体重指数而异。没有直接证据表明儿童期筛查或治疗对成年期的结果有任何益处或危害。强化饮食干预可能是安全的,具有不确定的临床意义的短期适度益处。
Cochrane Database Syst Rev. 2016-8-22
Evid Rep Technol Assess (Full Rep). 2007-8
Cochrane Database Syst Rev. 2018-7-5
Cochrane Database Syst Rev. 2023-2-8
Cochrane Database Syst Rev. 2005-7-20
JAMA Netw Open. 2024-7-1
Signal Transduct Target Ther. 2024-1-24
Diagnostics (Basel). 2024-1-8
Imaging Sci Dent. 2023-12
Metabolites. 2023-6-15